Facility Spotlight: Winnipeg, Manitoba, Canada

01.18.2023

For more than 30 years, our Winnipeg, Manitoba (Canada) site has offered a broad range of expertise for drug substance and drug product manufacturing. The 150,000-sq.ft. facility manufactures polyclonal hyperimmune products, plasma therapeutics, lipoproteins, and mRNA products, and houses a SA25 aseptic filling workcell — a gloveless, robotic isolator ideal for high-value biologic products.

Learn more about how our Winnipeg site is equipped to support your next clinical or commercial drug candidate.

Emergent CDMO

Video Video Library

01.13.2022

A look inside our Center of Excellence for Development Services

From analytical development to drug substance and drug product process development and scale-up, we can help advance your...

11.04.2022

Outsourced Pharma Capacity Update

Did you miss the large molecule Outsourced Pharma Capacity Update last month? Download the ondemand presentation to learn more...

07.23.2021

Arrival of the Groninger INTEGRA

With the expansion of our viral drug product manufacturing facility in Rockville, Maryland well underway, we have begun...